NasdaqGM:IOVABiotechs
Can Iovance (IOVA) Turn Early Amtagvi Data and Manufacturing Tweaks into a Durable Advantage?
Iovance Biotherapeutics recently announced that Interim CEO Fred Vogt and CFO Corleen Roche took part in a fireside chat at the 2026 Jefferies Global Healthcare Conference, while highlighting encouraging real-world data for its FDA-approved TIL therapy Amtagvi in advanced melanoma.
The combination of early commercial experience with Amtagvi and efforts to improve manufacturing efficiencies and pursue label expansions underscores how Iovance is trying to scale a complex cell therapy platform...